FDA Drug Manufacturing Oversight During Covid-19: The GAO Report on the Inspections Backlog and Steps FDA is Taking to Address It
Update Magazine | Summer 2021
Orphan Drugs in Canada: A “One Size Fits All” Regulatory Regime
Orphan Drugs in Canada: A “One Size Fits All” Regulatory Regime By Eileen McMahon and Denise Ramsden Introduction Medicines targeting rare diseases, also known as orphan drugs,[1] once faced an uphill battle for research funding and market approval. The need for robust commercial incentives to create rare disease treatments spurred the establishment [...]
Food and Supplement Class Action Suits That Rely on Alleged Regulatory Violations
Update Magazine | Summer 2021
Pharmaceutical GMPs, Quality Control, and Data: A Deeper Look at FDA’s FY 2020 FDA Observations
Update Magazine | Summer 2021
Letter to the Editor: Recent FDA Activity on Cannabis Clinical Research
Update Magazine | Summer 2021
Juul Labs: Advancing the Scientific Dialogue About Tobacco Harm Reduction
Update Magazine | Summer 2021
New Bioengineered (aka GM) Food Disclosure Law: Useful Information or Consumer Confusion?
Update Magazine | Summer 2021
